ALLO - Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Recently reported position changes by institutional investors
Recent trades by U.S. Senators
| Date |
Senator |
Type |
| 2/18/2020 |
Feinstein, Dianne |
Sale: None |
| 1/31/2020 |
Feinstein, Dianne |
Sale: None |
| 5/13/2019 |
Feinstein, Dianne |
Purchase: None |
Recent trades by U.S. Representatives
No data for this ticker
Quarterly net insider trading by a company's directors and management
Flights by private jets registered to ALLO
No data for this ticker
Federal grants, loans, and purchases. Click on a date for more info.
No data for this ticker
